BTR – Biomedical and Translational Research

Astrid Vicente

The overall aim of the Biomedical & Translational Group is to understand the interplay of biological – including genetic or epigenetic factors -, life style and environmental determinants that sustain a healthy life or lead to disease onset, and to translate this knowledge into better health promotion, disease prevention practices and improved diagnosis or therapies.

The BTR group gathers several research teams mainly contributing to the Biomedicine, Bioinformatics and Biophysics thematic strands, and cooperating with other thematic lines as new challenges arise. Each research team has been focusing on the dynamics of one or several disorders, on population health determinants and/or on therapy efficacy or adverse reactions, generating and analyzing information at multiple levels on large population datasets. The research teams are established in academic settings (e.g., Deafness group at FCUL), at the Portuguese public health institute (e.g., the Neurogenetics and Mental Health group, the Cardiovascular Disease group and the Cellular and Molecular Immunology group , all at INSA) or in a clinical research environment (the Molecular Pathology group at Hospital de Ponta Delgada).

BTR research teams gather and analyze multilevel data on large datasets of the general population or populations affected with multifactorial diseases, namely brain disorders (ASD, AD, HL and more recently language disabilities) and cardiovascular diseases (CVD) (including FH, ATH, CAD, MI, CHD and stroke).

For specific disease models, the BTR group will strategically focus on: 1) comprehensive data collection and analysis of health and disease determinants for identification of disease biomarkers, broader understanding of disease physiopathology and development of improved therapeutics ; 2) a holistic approach to research in individuals and populations, integrating multiple layers of information from socio-demographic to clinical to genomic; 3) personalized medicine, targeting the identification of factors influencing individual response to therapy, as well as the implementation of a database and biobank for pharmacogenomics.

Team

Group Leader: Astrid Vicente astrid.vicente@insa.min-saude.pt

Technicians: Leonor Abrantes | Joana Duarte | Lisa M. Esteves

Recent Publications

Characterization of Two Variants at Met 1 of the Human LDLR Gene Encoding the Same Amino Acid but Causing Different Functional Phenotypes

Graça, Rafael, Rafael Fernandes, Ana C. Alves, Juliane Menezes, Luísa Romão, and Mafalda Bourbon. (2021) Biomedicines 9, no. 9: 1219. https://doi.org/10.3390/biomedicines9091219

A comprehensive overview of the cystic fibrosis on the island of São Miguel (Azores, Portugal)

Rosa J, Gaspar-Silva P, Pacheco P, Silva C, Branco CC, Vieira BS, Carreiro A Gonçalves J Mota-Vieira L (2020) BMC Pediatrics 20(1); https://doi.org/10.1186/s12887-019-1903-y

The familial hypercholesterolaemia phenotype: Monogenic familial hypercholesterolaemia, polygenic hypercholesterolaemia and other causes

Mariano C, Alves AC, Medeiros AM, Chora JR, Antunes M, Futema M, Humphries SE, Bourbon M (2020) Clin Genet. 97(3):457-466; https://doi.org/10.1111/cge.13697

Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica

Alves AC, Alonso R, Diaz-Diaz JL, Medeiros AM, Jannes CE, Merchan A, Vasques-Cardenas NA, Cuevas A, Chacra AP, Krieger JE, Arroyo R, Arrieta F, Schreier L, Corral P, Bañares VG, Araujo MB, Bustos P, Asenjo S, Stoll M, Dell'Oca N, Reyes M, Ressia A, Campo R, Magaña-Torres MT, Metha R, Aguilar-Salinas CA, Ceballos-Macias JJ, Morales ÁJR, Mata P, Bourbon M, Santos RD (2020) Arterioscler Thromb Vasc Biol. 40(10):2508-2515; https://doi.org/10.1161/ATVBAHA.120.313722

Contrasting Photo-Switching Rates in Azobenzene Derivatives: How the Nature of the Substituent Plays a Role

Pirone D, Bandeira NAG, Tylkowski B, Boswell E, Labeque R, Valls RG, Giamberini M (2020) Polymers 12(5), 1019; https://doi.org/10.3390/polym12051019

How personalised medicine will transform healthcare by 2030: the ICPerMed vision

Vicente AM, Ballensiefen W, Jönsson J (2020) J Transl Med 18, 180; https://doi.org/10.1186/s12967-020-02316-w